dexamethasone + ulinastatin

Dexamethasone + ulinastatin is a combination therapy consisting of dexamethasone, a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties, and ulinastatin, a protease inhibitor derived from human urine that exhibits anti-inflammatory effects by inhibiting various serine proteases. This combination has been studied primarily for the treatment of sepsis, where it has demonstrated synergistic efficacy in reducing inflammatory markers, improving clinical scores (such as APACHE II and SOFA), and lowering adverse event rates compared to dexamethasone monotherapy. The mechanism involves suppression of systemic inflammation through both inhibition of pro-inflammatory cytokines (by dexamethasone) and reduction in protease-mediated tissue damage (by ulinastatin)[1][2][3][4].